🔥 🔥 Long-awaited final data from ACTT-1! 🔥 🔥

#Remdesivir decreased time to discharge but had no statistically significant mortality benefit at day 29.

Benefit seems limited to patients on supplemental oxygen (but not ventilated)

nejm.org/doi/full/10.10… Image
My conclusion: clearly there is a clinically meaningful benefit in patients who require supplemental oxygen but not higher levels of respiratory support.

Personally I would also use it in critically severe disease *if supply was not a constraint*. But unfortunately it is.
Thanks to the US “me-first” approach to hoarding remdesivir, minuscule supplies are available in Canada.

We were allocated 30 courses for the *entire province* (4.5 million people) outside of a clinical trial (which is not an option at most hospitals)
Consequently, it is imperative that we reserve it for patients most likely to derive benefit.

Based on the data in ACTT-1, this is indisputably patients requiring supplemental oxygen but not mechanically ventilated.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Ilan Schwartz MD PhD

Ilan Schwartz MD PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @GermHunterMD

11 Oct
How it started How its going ImageImage
How it started How it’s going ImageImage
How it started How it’s going ImageImage
Read 9 tweets
9 Oct
Undisputed champion of “Worst name in the history of naming organisms since Linnaeus”:

Myxococcus
llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogochensis

(Yes really)
If you can pronounce it, you will win a prize
Read 4 tweets
4 Jun
Origin story of the HCQ PEP trial.

I have learned a ton from working with @boulware_dr and @DrToddLee and team on this trial.

Most important lesson:

Don’t let the details (like funding for example) get in the way of doing something important.
This trial was run on a shoe-string using innovative internet-based recruitment and follow up with centralized depot and administration
A reminder of how the 🇺🇸🇨🇦 HCQ PEP trial came to be through #IDTwitter.

We didn’t have any details of how or if this would work... Todd just decided to get it done, adapting David’s protocol to Canada with support from colleagues in Manitoba & Alberta.

Read 8 tweets
30 May 19
Today I gave divisional rounds @UofA_ID on the power of #SoMe and #IDTwitter for ID physicians and microbiologists.

I have gained loads in this space, and here I compile some of the takeaways 🥡 for those who remain unconvinced of the benefits of #MedTwitter

A thread 1/
Whether we like it or not, #SoMe has changed our world. It has changed the way leaders are chosen, the way we communicate & interact with one another, the empowerment & mobilization of societies, & giving us unprecedented access to people and spaces otherwise unimaginable. 2/
#SoMe has also changed the way academic physicians and scientists practice and how we conduct and communicate science. 3/
Read 35 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!